SIM
ARCT icon

SummerHaven Investment Management’s Arcturus Therapeutics ARCT Stock Holding History

SummerHaven Investment Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-23,400
Closed -$570K – 203
2024
Q2 		$570K Buy
23,400
+409
+2% +$12.4K 0.37% 150
2024
Q1 		$776K Buy
22,991
+287
+1% +$10.2K 0.49% 115
2023
Q4 		$716K Buy
22,704
+378
+2% +$8.98K 0.46% 131
2023
Q3 		$570K Buy
+22,326
New +$688K 0.42% 163

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SummerHaven Investment Management's ARCT Position: Q3 2024 in Review

SummerHaven Investment Management sold out of Arcturus Therapeutics (ARCT) in Q3 2024, closing a stake of 23,400 shares — an estimated $570K sold.

SummerHaven Investment Management first reported a position in ARCT in Q3 2023 and held it in 4 quarters. The position peaked at $776K in Q1 2024. 164 funds tracked by Wall St. Rank hold ARCT as of Q3 2024.

  • SummerHaven Investment Management reported no remaining Arcturus Therapeutics position as of Q3 2024 after selling out during the quarter.
  • SummerHaven Investment Management sold 23,400 Arcturus Therapeutics shares in Q3 2024, an estimated $570K.
  • SummerHaven Investment Management first reported a position in Arcturus Therapeutics in Q3 2023 and held it in 4 quarters.
  • SummerHaven Investment Management's Arcturus Therapeutics position peaked at $776K in Q1 2024.
  • 164 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2024.

Based on SummerHaven Investment Management's 13F filing for Q3 2024, filed 16 Oct 2024.